Last updated: February 14, 2026
What Is the Therapeutic Profile of NDC 62332-0013?
NDC 62332-0013 corresponds to Blenrep (belantamab mafodotin-blmf), marketed by GlaxoSmithKline. It is approved for the treatment of relapsed or refractory multiple myeloma. The drug is a monoclonal antibody conjugated with a cytotoxic agent, targeting BCMA (B-cell maturation antigen).
Market Landscape
Multiple Myeloma Treatment Market
The multiple myeloma market is a fast-growing segment. The global market was valued at approximately $13.4 billion in 2022, projected to reach $20.5 billion by 2027, growing at a CAGR of 8.4% (source [1]). Key drivers include increased diagnosis, novel therapies, and relapsed/refractory patient populations.
Blenrep’s Competition and Positioning
Blenrep faces competition from other BCMA-targeted therapies:
| Drug |
Marketed By |
Approval Date |
Indication |
Price (approximate USD per dose) |
| Belantamab mafodotin (Blenrep) |
GlaxoSmithKline |
August 2020 |
Multiple myeloma (relapsed/refractory) |
$11,000 per 2.5 mg vial [2] |
| Carfilzomib (Kyprolis) |
Amgen |
2012 |
Multiple myeloma |
$4,500 per 60 mg vial [3] |
| Daratumumab (Darzalex) |
Janssen |
2015 |
Multiple myeloma |
$5,200 per 16 mg vial [4] |
| Elotuzumab (Empliciti) |
Bristol-Myers Squibb |
2015 |
Multiple myeloma |
$6,045 per 20 mg vial [5] |
The pricing indicates that Blenrep's upfront cost is higher relative to some competitors, reflecting its unique mechanism of action and marginal efficacy advantages.
Price Trends and Projections
Historical Pricing Trends
Blenrep’s wholesale acquisition cost (WAC) has remained roughly stable since launch, around $11,000 per vial. Such stability indicates limited price erosion amid increasing competition.
Future Market Dynamics
Given increased adoption, market penetration for Blenrep is projected to plateau at approximately 15% of relapsed/refractory multiple myeloma patients in the next 3 years, based on current prescribing patterns and clinical trial data (source [6]).
Projected Pricing
Price projections suggest:
- Stability in current pricing over the next 3-5 years unless new competitors or biosimilars emerge.
- Potential discounts possible as biosimilar or alternative therapies gain approval.
- Reimbursement policies could influence net prices, especially in cost-sensitive healthcare systems.
Assumptions for Projections:
- No significant price reductions due to biosimilar entry.
- Steady demand growth aligned with market expansion.
- No major regulatory or patent challenges affecting pricing.
Estimated Price Range (2023-2028)
| Year |
Estimated Price per Vial (USD) |
Notes |
| 2023 |
$11,000 |
Current wholesale price |
| 2024 |
$11,000 - $10,500 |
Potential slight discounts possible |
| 2025 |
$10,500 |
Slight erosion owing to market competition |
| 2026 |
$10,500 |
Market stabilization |
| 2027 |
$10,500 |
No significant change expected |
| 2028 |
$10,500 |
Entry of biosimilars or new competitors |
Implications for Stakeholders
- Pharmaceutical companies: Opportunities to develop biosimilars or adjunct therapies.
- Payers: Increasing pressure to negotiate discounts, especially if competitive therapies grow.
- Investors: Stable pricing indicates limited near-term decline risks absent patent challenges or market saturation.
Key Takeaways
- Blenrep (belantamab mafodotin-blmf) entered a competitive BCMA-targeted therapy market with a high initial price.
- Current wholesale cost remains around $11,000 per vial, with expectations of stability over the next five years.
- Market growth is driven by an increasing multiple myeloma patient population, but price erosion may occur as biospires or alternative therapies gain approval.
- Industry trends toward biosimilars and cost containment could influence future pricing strategies.
FAQs
Q1: How does Blenrep's price compare to other multiple myeloma therapies?
Blenrep’s cost (~$11,000/vial) exceeds most monoclonal antibodies like Daratumumab (~$5,200/vial) but is similar or slightly higher than other BCMA therapies such as CAR-T treatments, which can reach $400,000+ upfront.
Q2: Is Blenrep likely to face biosimilar competition?
Yes, pending patent expiration and regulatory approval, biosimilars could enter markets within 5-7 years, likely leading to price reductions.
Q3: What factors influence Blenrep’s future price?
Regulatory landscape, clinical efficacy data, competitive landscape, biosimilar entry, and healthcare reimbursement policies.
Q4: How is the adoption rate expected to affect pricing?
Higher uptake could support stable prices; slower adoption or increased competition could pressure prices downward.
Q5: What is the primary revenue driver for Blenrep?
Sales volume driven by prescribing guidelines and market penetration, with price stability maintaining revenue per unit.
Sources
[1] MarketsandMarkets. “Multiple Myeloma Market by Drug Class, Route of Administration, and Region — Global Forecast to 2027.”
[2] GSK. “Blenrep (belantamab mafodotin-blmf) Prescribing Information,” 2020.
[3] GoodRx. “Kyprolis (carfilzomib) Pricing,” 2022.
[4] Janssen. “Daratumumab (Darzalex) Pricing,” 2023.
[5] Bristol-Myers Squibb. “Empliciti (elotuzumab) Pricing,” 2022.
[6] IQVIA Institute. “The Global Use of Medicines in 2022,” 2022.
